{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:44:59Z","timestamp":1795211099376,"version":"4.10.3"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014039","name":"Department of Defense Prostate Cancer Research Program","doi-asserted-by":"publisher","award":["W81XWH-16-1-0433"],"award-info":[{"award-number":["W81XWH-16-1-0433"]}],"id":[{"id":"10.13039\/100014039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014039","name":"Department of Defense Prostate Cancer Research Program","doi-asserted-by":"publisher","award":["W81XWH-19-1-0712"],"award-info":[{"award-number":["W81XWH-19-1-0712"]}],"id":[{"id":"10.13039\/100014039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["HHSN261200800001E"],"award-info":[{"award-number":["HHSN261200800001E"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.eururo.2021.03.009","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T18:13:53Z","timestamp":1616868833000},"page":"746-757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy"],"prefix":"10.1016","volume":"80","author":[{"given":"Scott","family":"Wilkinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Karzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Harmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas T.","family":"Terrigino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"VanderWeele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Bright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayann","family":"Atway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shana Y.","family":"Trostel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole V.","family":"Carrabba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichelle C.","family":"Whitlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosina T.","family":"Lis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houssein","family":"Abdul Sater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Capaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi A.","family":"Madan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Gulley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guinevere","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela C.","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsimar B.","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara L.","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Venzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Choyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Turkbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Dahut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2760-1853","authenticated-orcid":false,"given":"Adam G.","family":"Sowalsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2021.03.009_bib0005","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2021.03.009_bib0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/MOU.0000000000000279","article-title":"Clonality of localized and metastatic prostate cancer","volume":"26","author":"Boutros","year":"2016","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2021.03.009_bib0015","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2021.03.009_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.03.029","article-title":"The evolutionary landscape of localized prostate cancers drives clinical aggression","volume":"173","author":"Espiritu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2021.03.009_bib0025","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41586-019-1907-7","article-title":"The evolutionary history of 2,658 cancers","volume":"578","author":"Gerstung","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2021.03.009_bib0030","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2021.03.009_bib0035","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2021.03.009_bib0040","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.eururo.2014.05.038","article-title":"Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial","volume":"66","author":"Attard","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.03.009_bib0045","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","article-title":"Abiraterone in \u201chigh-\u201d and \u201clow-risk\u201d metastatic hormone-sensitive prostate cancer","volume":"76","author":"Hoyle","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.03.009_bib0050","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2021.03.009_bib0055","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","article-title":"Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study","volume":"32","author":"Taplin","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.03.009_bib0060","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1158\/1078-0432.CCR-16-1357","article-title":"Neoadjuvant enzalutamide prior to prostatectomy","volume":"23","author":"Montgomery","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2021.03.009_bib0065","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1200\/JCO.18.01777","article-title":"Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone","volume":"37","author":"McKay","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.03.009_bib0070","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1158\/1078-0432.CCR-20-2344","article-title":"Sequential prostate magnetic resonance imaging in newly diagnosed high-risk prostate cancer treated with neoadjuvant enzalutamide is predictive of therapeutic response","volume":"27","author":"Karzai","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2021.03.009_bib0075","doi-asserted-by":"crossref","unstructured":"McKay RR, Berchuck J, Kwak L, et al. Outcomes post neoadjuvant intense hormone therapy and surgery for patients with high-risk localized prostate cancer: results of a pooled analysis of contemporary clinical trials. J Urol. In press. https:\/\/doi.org\/10.1097\/ju.0000000000001632.","DOI":"10.1097\/JU.0000000000001632"},{"key":"10.1016\/j.eururo.2021.03.009_bib0080","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1158\/1078-0432.CCR-14-1220","article-title":"Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors","volume":"21","author":"Chen","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2021.03.009_bib0085","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1158\/0008-5472.CAN-18-0610","article-title":"Neoadjuvant-intensive androgen deprivation therapy selects for prostate tumor foci with diverse subclonal oncogenic alterations","volume":"78","author":"Sowalsky","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2021.03.009_bib0090","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2021.03.009_bib0095","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Cancer Genome Atlas Research Network","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2021.03.009_bib0100","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2021.03.009_bib0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2021.03.009_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in The Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2021.03.009_bib0115","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/0008-5472.CAN-12-2799","article-title":"Clonal progression of prostate cancers from Gleason grade 3 to grade 4","volume":"73","author":"Sowalsky","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2021.03.009_bib0120","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41467-020-14657-7","article-title":"A case report of multiple primary prostate tumors with differential drug sensitivity","volume":"11","author":"Wilkinson","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2021.03.009_bib0125","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/pros.23212","article-title":"Mutation profiling indicates high grade prostatic intraepithelial neoplasia as distant precursors of adjacent invasive prostatic adenocarcinoma","volume":"76","author":"Gerrin","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2021.03.009_bib0130","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1158\/1078-0432.CCR-16-2414","article-title":"Gleason score 7 prostate cancers emerge through branched evolution of clonal Gleason pattern 3 and 4","volume":"23","author":"Sowalsky","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2021.03.009_bib0135","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cell.2013.03.021","article-title":"Punctuated evolution of prostate cancer genomes","volume":"153","author":"Baca","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2021.03.009_bib0140","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","article-title":"Genomic and phenotypic heterogeneity in prostate cancer","volume":"18","author":"Haffner","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2021.03.009_bib0145","doi-asserted-by":"crossref","unstructured":"Abrams-Pompe RS, Fanti S, Schoots IG, et al. The role of magnetic resonance imaging and positron emission tomography\/computed tomography in the primary staging of newly diagnosed prostate cancer: a systematic review of the literature. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2020.11.002.","DOI":"10.1016\/j.euo.2020.11.002"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283821002074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283821002074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:52:44Z","timestamp":1777549964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283821002074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0302283821002074"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2021.03.009","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.09.29.20199711","asserted-by":"object"}]},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2021.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}